Table 3.

Ongoing phase II and III trials testing novel compounds.

Study	Ph	Treatment	Population	Nr.
NCT05555732	III	Datopotamab Deruxtecan + Pembrolizumab with or without chemotherapy	No Prior Therapy for Advanced or Metastatic PD-L1 TPS < 50% nonsquamous NSCLC without Actionable Genomic Alterations	975
NCT05215340	III	Datopotamab Deruxtecan + Pembrolizumab vs. Pembrolizumab	Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥ 50%) NSCLC without Actionable Genomic Alterations	740
NCT05089734	III	Sacituzumab Govitecan vs. Docetaxel	Metastatic NSCLC with Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	580
NCT05186974	II	Sacituzumab Govitecan + Pembrolizumab with or without platinum-based chemotherapy	First-line Treatment of Patients with Metastatic NSCLC Without Actionable Genomic Alterations	224
NCT04154956	III	SAR408701 vs. Docetaxel	Previously Treated, CEACAM5 Positive Metastatic nonsquamous NSCLC	450
NCT05245071	II	SAR408701	Nonsquamous NSCLC Participants with Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA	38
NCT04524689	II	SAR408701 + Pembrolizumab with or without platinum-based chemotherapy	CEACAM5 Positive Expression Advanced/Metastatic nonsquamous NSCLC not previously treated	120
NCT04928846	III	Telisotuzumab-Vedotin vs. Docetaxel	Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic nonsquamous NSCLC	698
NCT05513703	II	Telisotuzumab-Vedotin	Previously Untreated MET Amplified Locally Advanced/Metastatic nonsquamous NSCLC	70
NCT03976375	III	Lenvatinib + Pembrolizumab vs. Docetaxel	Previously Treated Metastatic NSCLC and Progressive Disease after Platinum Doublet Chemotherapy and Immunotherapy	405
NCT05633602	III	Ramucirumab + Pembrolizumab vs. standard of care	Previously Treated with Immunotherapy for Stage IV or Recurrent NSCLC	700